| 摘要 |
Unlabeled probe (I) comprises a target-specific sequence (Ia) of 6-30 nucleotides (nt), and first and second arms (A1, A2), each at least 10 nt long, positioned 5' and 3' with respect to (Ia). (Ia) is not complementary to any part of (I) but A1 and A2 are perfectly complementary with each other. Independent claims are also included for: (1) biochip (BC) comprising at least two (I) on a support; (2) universal, unlabeled addressing system (UUAS) comprising BC and unlabeled, non-immobilized probes (II); (3) kit comprising BC and at least one additional reagent; (4) method for detecting nucleic acid (NA), using BC or UUAS; (5) ex vivo method for detecting a genetic variant, any organism that contains NA or an alternative splicing product of a gene, using BC or UUAS; (6) ex vivo method for sequencing an oligonucleotide that uses BC or UUAS; and (7) ex vivo method for detecting allelic disequilibrium or loss of heterozygosity, using BC or UUAS. |
